No Data
No Data
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2024 Earnings and Company Updates
Truist Financial Maintains Intellia Therapeutics(NTLA.US) With Buy Rating
Intellia Therapeutics Receives Backing of UK Health Regulator to Conduct Trial of Gene Therapy
Express News | Intellia Therapeutics Receives Authorization To Initiate Phase 1/2 Clinical Trial Of NTLA-3001 For Treating Alpha-1 Antitrypsin Deficiency
Express News | Intellia Therapeutics Inc - Ntla-3001 Study to Enroll up to 30 Patients
Express News | Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of Ntla-3001 for the Treatment of Alpha-1 Antitrypsin Deficiency
No Data
10baggerbamm : why is anybody even bothering with this woman she's been negative year-to-date she is no conviction she gives price targets pie in the sky and if she really believed in them she would not be selling these companies she's full of shit she made money one year one time everything else has been a disaster
tankeng : yes this woman has problems and arrogant